Literature DB >> 9585386

Low IGF-I levels are often uncoupled with elevated GH levels in catabolic conditions.

L Gianotti1, F Broglio, G Aimaretti, E Arvat, S Colombo, M Di Summa, G Gallioli, G Pittoni, E Sardo, M Stella, M Zanello, C Miola, E Ghigo.   

Abstract

Increased GH together with decreased IGF-I levels pointing to peripheral GH insensitivity in critically ill patients have been reported by some but not by other authors. To clarify whether elevated GH levels are coupled with low IGF-I levels in all catabolic conditions, basal GH and IGF-I levels were evaluated in patients with sepsis (SEP, no.=13; age [mean+/-SE]=59.2+/-1.2 yr), trauma (TRA, no.=16; age=42.3+/-3.4 yr), major burn (BUR, no.=26; age=52.8+/-4.2 yr) and post-surgical patients (SUR, no.=11; age=55.0+/-4.7 yr) 72 hours after ICU admission or after cardiac surgery. GH and IGF-I levels were also evaluated in normal subjects (NS, no.=75; age=44.0+/-1.5 yr), in adult hypopituitaric patients with severe GH deficiency (GHD, no.=54; age=44.8+/-2.3 yr), in patients with liver cirrhosis (LC, no.=12; age=50.4+/-2.8 yr) and in patients with anorexia nervosa (AN, no.=19; age=18.7+/-0.8 yr). Basal IGF-I and GH levels in GHD were lower than in NS (68.6+/-6.4 vs 200.9+/-8.7 microg/l and 0.3+/-0.1 vs 1.4+/-0.2 microg/l; p<0.01). On the other hand, AN and LC showed IGF-I levels (70.4+/-9.1 and 52.4+/-10.5 microg/l) similar to those in GHD while GH levels (10.0+/-2.8 and 7.9+/-2.1 microg/l) were higher than those in NS (p<0.01). IGF-I levels in SEP (84.5+/-8.8 microg/l) were similar to those in GHD, AN and LC and lower than those in NS (p<0.01). IGF-I levels in BUR (105.2+/-10.9 microg/l) were lower than in NS (p<0.01) but higher than those in GHD, AN, LC and SEP (p<0.01). On the other hand, in TRA (162.8+/-17.4 microg/l) and SUR (135.0+/-20.7 microg/l) IGF-I levels were lower but not significantly different from those in NS and clearly higher than those in GHD, AN, LC, SEP and BUR. Basal GH levels in SEP (0.6+/-0.2 microg/l), TRA (1.8+/-0.5 microg/l), SUR (2.2+/-0.5 microg/l) and BUR (2.2+/-0.5 microg/l) were similar to those in NS, higher (p<0.05) than those in GHD and lower (p<0.01) than those in AN and LC. In conclusion, our data demonstrate that low IGF-I levels are not always coupled with elevated GH levels in all catabolic conditions. Differently from cirrhotic and anorectic patients, in burned and septic patients GH levels are not elevated in spite of very low IGF-I levels similar to those in panhypopituitaric GHD patients. These findings suggest that in some catabolic conditions peripheral GH insensitivity and somatotrope insufficiency could be concomitantly present.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9585386     DOI: 10.1007/BF03350325

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  50 in total

1.  The somatotropic axis in critical illness: effect of continuous growth hormone (GH)-releasing hormone and GH-releasing peptide-2 infusion.

Authors:  G Van den Berghe; F de Zegher; J D Veldhuis; P Wouters; M Awouters; W Verbruggen; M Schetz; C Verwaest; P Lauwers; R Bouillon; C Y Bowers
Journal:  J Clin Endocrinol Metab       Date:  1997-02       Impact factor: 5.958

Review 2.  Nutritional regulation of the insulin-like growth factors.

Authors:  J P Thissen; J M Ketelslegers; L E Underwood
Journal:  Endocr Rev       Date:  1994-02       Impact factor: 19.871

3.  Effects of recombinant human growth hormone on donor-site healing in severely burned children.

Authors:  D N Herndon; R E Barrow; K R Kunkel; L Broemeling; R L Rutan
Journal:  Ann Surg       Date:  1990-10       Impact factor: 12.969

4.  Expression of IGF-I and IGF-binding protein genes in cirrhotic liver.

Authors:  R J Ross; S L Chew; L D'Souza Li; M Yateman; J Rodriguez-Arnao; A Gimson; J Holly; C Camacho-Hubner
Journal:  J Endocrinol       Date:  1996-05       Impact factor: 4.286

Review 5.  Physiology of growth hormone secretion and action.

Authors:  F F Casanueva
Journal:  Endocrinol Metab Clin North Am       Date:  1992-09       Impact factor: 4.741

6.  Temporal structure of in vivo growth hormone secretory events in humans.

Authors:  M L Hartman; A C Faria; M L Vance; M L Johnson; M O Thorner; J D Veldhuis
Journal:  Am J Physiol       Date:  1991-01

7.  Effects of recombinant human growth hormone in patients with severe sepsis.

Authors:  H J Voerman; R J van Schijndel; A B Groeneveld; H de Boer; J P Nauta; E A van der Veen; L G Thijs
Journal:  Ann Surg       Date:  1992-12       Impact factor: 12.969

8.  Critically ill patients have high basal growth hormone levels with attenuated oscillatory activity associated with low levels of insulin-like growth factor-I.

Authors:  R Ross; J Miell; E Freeman; J Jones; D Matthews; M Preece; C Buchanan
Journal:  Clin Endocrinol (Oxf)       Date:  1991-07       Impact factor: 3.478

9.  Critical illness is associated with low circulating concentrations of insulin-like growth factors-I and -II, alterations in insulin-like growth factor binding proteins, and induction of an insulin-like growth factor binding protein 3 protease.

Authors:  A C Timmins; A M Cotterill; S C Hughes; J M Holly; R J Ross; W Blum; C J Hinds
Journal:  Crit Care Med       Date:  1996-09       Impact factor: 7.598

10.  Arginine but not pyridostigmine, a cholinesterase inhibitor, enhances the GHRH-induced GH rise in patients with anorexia nervosa.

Authors:  E Ghigo; E Arvat; L Gianotti; M Nicolosi; M R Valetto; S Avagnina; D Bellitti; M Rolla; E E Müller; F Camanni
Journal:  Biol Psychiatry       Date:  1994-11-15       Impact factor: 13.382

View more
  5 in total

1.  Activity of GH/IGF-I axis in trauma and septic patients during artificial nutrition: different behavior patterns?

Authors:  G Pittoni; G Gallioi; M Zanello; L Gianotti; M F Boghen; S Colombo; F Broglio; C Santoro; G Davià; M G Papini; S Destefanis; F Minuto; C Miola; E Ghigo
Journal:  J Endocrinol Invest       Date:  2002-03       Impact factor: 4.256

2.  Normal IGF-I and enhanced IGFBP-3 response to very low rhGH dose in patients with dilated cardiomyopathy.

Authors:  F Broglio; A Benso; E Arvat; G Aimaretti; C Gottero; R Granata; M F Boghen; M Bobbio; F Camanni; E Ghigo
Journal:  J Endocrinol Invest       Date:  2000-09       Impact factor: 4.256

3.  Activity of GH/IGF-1 axis in burn patients: comparison with normal subjects and patients with GH deficiency.

Authors:  L Gianotti; M Stella; D Bollero; F Broglio; F Lanfranco; G Aimaretti; S Destefanis; M Casati; G Magliacani; E Ghigo
Journal:  J Endocrinol Invest       Date:  2002-02       Impact factor: 4.256

Review 4.  GH/IGF1 axis disturbances in the fibromyalgia syndrome: is there a rationale for GH treatment?

Authors:  G Cuatrecasas; C Alegre; F F Casanueva
Journal:  Pituitary       Date:  2014-06       Impact factor: 4.107

5.  Insulin-like growth factor I (IGF-I) as a sensitive biomarker of catabolism in patients with gastrointestinal diseases.

Authors:  Olgica Nedić; Vesna Malenković; Judith Anna Nikolić; Ivona Baricević
Journal:  J Clin Lab Anal       Date:  2007       Impact factor: 2.352

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.